Study Summary
This trialtests if a new drug is safe and effective for treating tumors that have a particular receptor.
- Colon Cancer
- Cervical Cancer
- Hormone-Refractory Prostate Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer
- Skin Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: 24 months
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
²¹²Pb-DOTAM-GRPR1
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: ²¹²Pb-DOTAM-GRPR1 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many different sites are administering this trial?
"At the moment, this medical trial is enrolling participants at 4 sites. These are found in Lexington, Glen Burnie and Omaha with one other site as well. It is best to choose a nearby location so you can cut down on travel arrangements if you decide to participate." - Anonymous Online Contributor
Is participation in this research endeavor currently attainable for people?
"As per the latest update on clinicaltrials.gov, this trial is actively enrolling patients. It was initially opened to applicants on December 22nd 2022 and has been updated most recently on January 24th 2023." - Anonymous Online Contributor
How many people are currently enrolled in this medical experiment?
"This trial requires 50 eligible participants to fulfill the requirements, and they can enrol from either UK Markey Cancer Center in Lexington or 331 Oak Manor Dr STE 201 in Glen Burnie." - Anonymous Online Contributor
Has the U.S. Food and Drug Administration certified ²¹²Pb-DOTAM-GRPR1?
"Due to its Phase 1 trial status, with limited data supporting safety and efficacy, our team has provisionally assigned ²¹²Pb-DOTAM-GRPR1 a score of 1 on the safety scale." - Anonymous Online Contributor